CD14 and Stroke: As such, it is conceivable to speculate that therapeutic strategies that aim at specifically reducing the number of intermediate monocytes (CD14++CD16+) in blood circulation in the acute phase of ischemic stroke, while increasing the number of non-classical monocytes (CD14+CD16++) might limit brain injury and reduce the risk of developing post-stroke complications.